While MET and RAPA have a similar effect on the inhibition of mTORC1, which may be beneficial for their combination on neuroprotection in PD, the outcome of the combination could be affected by their distinct effects on AMPK and Akt. The gene discussed is MET; the disease is Parkinson disease.